Yubo International Biotech Limited

Equities

YBGJ

US9883661004

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:51:59 2024-04-12 am EDT			5-day change	1st Jan Change
0.95 ^USD	-0.78%		0.00%	+216.67%

Apr. 12	Yubo International Biotech Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Yubo International Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Yubo International Biotech Limited Reports Earnings Results for the First Quarter Ended March 31, 2022

May 16, 2022 at 04:30 pm EDT

Yubo International Biotech Limited reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 0.015213 million compared to USD 0.462329 million a year ago. Net loss was USD 0.578948 million compared to USD 0.438675 million a year ago.

Latest news about Yubo International Biotech Limited

Yubo International Biotech Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 12	CI
Yubo International Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Yubo International Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Yubo International Biotech Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Yubo International Biotech Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Yubo International Biotech Limited Auditor Raises 'Going Concern' Doubt	23-04-13	CI
Yubo International Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16	CI
Insider Sell: Yubo International Biotech	22-11-10	MT
Yubo International Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Yubo International Biotech Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Yubo International Biotech Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Yubo International Biotech Limited Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Yubo International Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Yubo International Biotech Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-20	CI
Yubo International Biotech Limited Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-24	CI
Yubo International Biotech Limited Changes Fiscal Year End from the Last Calendar Day of February to December 31	21-02-05	CI
Platinum International Biotech Co., Ltd acquired Yubo International Biotech Limited for approximately $380 million in a reverse merger transaction.	21-01-13	CI

Chart Yubo International Biotech Limited

Duration

Period

Chart Yubo International Biotech Limited

More charts

Company Profile

Yubo International Biotech Ltd, formerly Magna-Lab Inc, is a holding company primarily operating through its subsidiary. The Company focuses on the research and development and application of endometrial stem cells and offers its products and services under the brand VIVCELL. The Companyâs product offerings include healthcare products for respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. The Company also offers stem cell related services including cell testing and health management consulting services.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
YUBO INTERNATIONAL BIOTECH LIMITED	+216.67%	114M
IQVIA HOLDINGS INC.	+1.12%	42.59B
MODERNA, INC.	+6.77%	40.65B
LONZA GROUP AG	+47.64%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B

Other Biotechnology & Medical Research